

11/21/00

315 U.S. PTO

11-22-00

A Box  
see

Express Mail Label No. EL777534297US

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
DEX-0115

Total Pages in this Submission

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING CANCER**

and invented by:

Salceda et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

### Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 28 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☒ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

315 U.S. PTO  
09/17/88

11/21/00

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
DEX-0115

Total Pages in this Submission

## Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)  
a. ☐ Formal      b. ☐ Informal      Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration  
a. ☐ Newly executed (original or copy)      ☒ Unexecuted  
b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)  
c. ☒ With Power of Attorney      ☐ Without Power of Attorney  
d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☒ Genetic Sequence Submission (if applicable, all must be included)  
a. ☒ Paper Copy  
b. ☒ Computer Readable Copy  
c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & documents)
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449      ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing  
☐ First Class      ☒ Express Mail (Specify Label No.): EL777534297US

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
DEX-0115

Total Pages in this Submission

## Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: \_\_\_\_\_
17. ☒ Additional Enclosures (please identify below):

Credit Card Payment Form

## Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

## Warning

**An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.**

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
DEX-0115

Total Pages in this Submission

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	16	- 20 =	0	x \$9.00	\$0.00
Indep. Claims	11	- 3 =	8	x \$40.00	\$320.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$355.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$675.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **50-1619** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: November 21, 2000



**26259**  
PATENT TRADEMARK OFFICE

CC:

*Kathleen A. Tyrrell*  
Signature

**Kathleen A. Tyrrell**  
Reg. No. 38,350  
Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, NJ 08053  
Tel: 856-810-1515  
Fax: 856-810-1454

**A NOVEL METHOD OF DIAGNOSING,  
MONITORING, STAGING, IMAGING AND TREATING CANCER**

**INTRODUCTION**

This application claims the benefit of priority from  
5 U.S. provisional application Serial No. 60/166,818, filed  
November 22, 1999.

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed  
assays for detecting, diagnosing, monitoring, staging,  
10 prognosticating, imaging and treating cancers, particularly  
ovarian cancer.

**BACKGROUND OF THE INVENTION**

In women, gynecologic cancers account for more than one-  
15 fourth of the malignancies. Carcinoma of the ovary is a very  
common gynecologic cancer. Approximately one in 70 women will  
develop ovarian cancer during her lifetime and in 1995 there  
were an estimated 14,500 deaths from ovarian cancer. In fact,  
ovarian cancer causes more deaths than any other cancer of the  
20 female reproductive system.

Ovarian cancer often does not cause any noticeable  
symptoms. Some possible warning signals include an enlarged  
abdomen due to an accumulation of fluid or vague digestive  
disturbances (discomfort, gas or distention) in women over 40;  
25 rarely there will be abnormal vaginal bleeding.

Periodic, complete pelvic examinations are important in  
the detection of ovarian cancer; a Pap test does not detect  
ovarian cancer. Annual pelvic exams are recommended for women  
over 40.

001211 000000

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating cancers are of critical importance to the outcome of the patient. Patients diagnosed early generally have a much greater five-year survival rate  
5 as compared to the survival rate for patients diagnosed with distant metastasized cancer. New diagnostic methods which are more sensitive and specific for detecting early cancers are clearly needed.

Cancer patients are closely monitored following initial  
10 therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. Thus, there is also clearly a need for cancer markers which are more sensitive and specific in detecting cancer recurrence.

Another important step in managing cancer is to determine  
15 the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of cancer is preferable over clinical staging because the former gives  
20 a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of cancer would be improved by detecting new markers in cells,  
25 tissues or bodily fluids which could differentiate between different stages of invasion.

A new marker, referred to herein as Ovr107, has now been identified for use in diagnosing, monitoring, staging, imaging and treating various cancers, and in particular ovarian  
30 cancer. Accordingly, the present invention relates to new methods for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo* imaging and treating cancer via Ovr107. Ovr107 refers, among other things, to native proteins expressed by the gene comprising the polynucleotide sequence  
35 of SEQ ID NO:1. By "Ovr107" it is also meant herein

polynucleotides which, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1, but which still encode the same protein. In the alternative, what is meant by Ovr107 as used herein, means the native mRNA encoded by the gene comprising SEQ ID NO:1 or it can refer to the actual gene comprising SEQ ID NO:1, or levels of a polynucleotide which is capable of hybridizing under stringent conditions to the antisense sequence of SEQ ID NO:1.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a diagnostic marker for cancer comprising Ovr107.

Further provided is a method for diagnosing the presence cancer by analyzing for changes in levels of Ovr107 in cells, tissues or bodily fluids compared with levels of Ovr107 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of Ovr107 in the patient versus the normal human control is associated with cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having cancer which is not known to have metastasized by identifying a human patient suspected of having cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for Ovr107;

comparing the Ovr107 levels in such cells, tissues, or bodily fluid with levels of Ovr107 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the patient versus the  
5 normal human control is associated with cancer which has metastasized.

Also provided by the invention is a method of staging cancer in a human with cancer by identifying a human patient having cancer; analyzing a sample of cells, tissues, or bodily  
10 fluid from such patient for Ovr107; comparing Ovr107 levels in such cells, tissues, or bodily fluid with levels of Ovr107 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the patient versus the normal human control is  
15 associated with a cancer which is progressing and a decrease in the levels of Ovr107 is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring cancer in a human patient for the onset of metastasis. The method  
20 comprises identifying a human patient having cancer that is not known to have metastasized; periodically analyzing cells, tissues, or bodily fluid from such patient for Ovr107; comparing the Ovr107 levels in such cells, tissue, or bodily fluid with levels of Ovr107 in preferably the same cells,  
25 tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in  
30 stage of cancer in a human patient by looking at levels of Ovr107 in the human patient. The method comprises identifying a human patient having cancer; periodically analyzing cells, tissues, or bodily fluid from such patient for Ovr107; comparing the Ovr107 levels in such cells, tissue, or bodily  
35 fluid with levels of Ovr107 in preferably the same cells,

05717883-142400



tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of Ovr107 is  
5 associated with a cancer which is regressing or in remission.

Further provided are methods of designing new therapeutic agents targeted to Ovr107 for use in imaging and treating cancer. For example, in one embodiment, therapeutic agents such as antibodies targeted against Ovr107 or fragments of  
10 such antibodies can be used to treat, detect or image localization of Ovr107 in a patient for the purpose of detecting or diagnosing a disease or condition. In this embodiment, an increase in the amount of labeled antibody detected as compared to normal tissue would be indicative of  
15 tumor metastases or growth. Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those  
20 derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. Therapeutics agents such as small molecules and antibodies or  
25 fragments thereof which decrease the concentration and/or activity of Ovr107 can also be used in the treatment of diseases characterized by overexpression of Ovr107. Such agents can be readily identified in accordance with teachings herein.

30 Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of  
35 the invention, are given by way of illustration only. Various

09717889 112100

changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

## 5 DESCRIPTION OF THE INVENTION

The present invention relates to, inter alia, diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, prognosticating, in vivo imaging and treating cancers by comparing levels of

10 Ovr107 with those of Ovr107 in a normal human control. Ovr107 refers, among other things, to native proteins expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1. By "Ovr107" it is also meant herein polynucleotides which, due to degeneracy in genetic coding, comprise

15 variations in nucleotide sequence as compared to SEQ ID NO: 1, but which still encode the same protein. In the alternative, what is meant by Ovr107 as used herein, means the native mRNA encoded by the gene comprising SEQ ID NO:1 or it can refer to the actual gene comprising SEQ ID NO:1, or levels

20 of a polynucleotide which is capable of hybridizing under stringent conditions to the antisense sequence of SEQ ID NO:1. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic

25 assay in accordance with the invention for diagnosing over-expression of Ovr107 protein compared to normal control bodily fluids, cells, or tissue samples can be used to diagnose the presence of cancers, including ovarian cancer. Ovr107 may be measured alone in the methods of the invention, or, more

30 preferably, in combination with other diagnostic markers for cancer. Thus, it is preferred that the methods of the present invention be employed in combination with measurement of the levels of other cancer markers as well as Ovr107. Other cancer markers, in addition to Ovr107, useful in the present

097387-112100

invention will depend on the cancer being tested and are known to those of skill in the art.

Detection of Ovr107 is particularly useful in ovarian cancer. However, this marker is also useful in the diagnosis, prognosis, staging, imaging and treatment of other types of cancer.

#### ***Diagnostic Assays***

The present invention provides methods for diagnosing the presence of cancer, including ovarian cancer, by analyzing for changes in levels of Ovr107 in cells, tissues or bodily fluids from a human patient compared with levels of Ovr107 in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of Ovr107 in the patient versus the normal human control is associated with the presence of cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of a cancer marker, such as Ovr107, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic cancer, including metastatic ovarian cancer, in a patient having a cancer which has not yet metastasized. In the method of the present invention, a human cancer patient suspected of having cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of ovarian cancer, patients are typically diagnosed with ovarian cancer following traditional detection methods.

In the present invention, determining the presence of Ovr107 in cells, tissues, or bodily fluid, is particularly

0971783-1100  
007277 "E8827650

useful for discriminating between cancers which have not metastasized and cancers which have metastasized. Existing techniques have difficulty discriminating between a cancer which has metastasized and a cancer which has not metastasized. However, proper treatment selection is often dependent upon such knowledge.

In the present invention, one of the cancer marker levels measured in cells, tissues, or bodily fluid of a human patient is Ovr107. Levels in the human patient are compared with levels of Ovr107 in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is Ovr107 in serum, this level is preferably compared with the level of Ovr107 in serum of a normal human control. An increase in Ovr107 in the human patient versus the normal human control is associated with a cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of a cancer marker, such as Ovr107, are at least two times higher, and more preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing metastasis or monitoring for metastasis, normal human control preferably includes samples from a human patient that is determined by reliable methods to have a cancer such as ovarian cancer which has not metastasized, such as samples from the same patient prior to metastasis.

#### **Staging**

The invention also provides a method of staging cancers in a human patient.

The method comprises identifying a human patient having cancer and analyzing a sample of cells, tissues, or bodily fluid from such patient for Ovr107. The measured Ovr107 levels are then compared to levels of Ovr107 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of Ovr107 is associated with a cancer which is regressing or in remission.

#### **Monitoring**

Further provided is a method of monitoring cancer in a human patient for the onset of metastasis. The method comprises identifying a human patient having cancer that is not known to have metastasized; periodically analyzing cells, tissues, or bodily fluid from such patient for Ovr107; and comparing the Ovr107 levels in such cells, tissue, or bodily fluid with levels of Ovr107 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of a cancer. The method comprises identifying a human patient having cancer; periodically analyzing cells, tissues, or bodily fluid from such patient for Ovr107; and comparing the Ovr107 levels in such cells, tissue, or bodily fluid with levels of Ovr107 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in Ovr107 levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of Ovr107 is associated with a cancer which is regressing in stage or in remission.

Monitoring such patients for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be performed more or less frequently depending on the cancer, the particular patient, and the stage of the cancer.

5 ***Prognostic Testing and Clinical Trial Monitoring***

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased levels of Ovr107. The present invention provides a method in  
10 which a test sample is obtained from a human patient and Ovr107 is detected. The presence of higher Ovr107 levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly ovarian cancer.

15 The effectiveness of therapeutic agents to decrease expression or activity of Ovr107 can also be monitored by analyzing levels of expression of Ovr107 in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can  
20 serve as a marker, indicative of the physiological response of the human patient, or cells as the case may be, to the agent being tested.

***Detection of genetic lesions or mutations***

The methods of the present invention can also be used to  
25 detect genetic lesions or mutations in Ovr107, thereby determining if a human with the genetic lesion is at risk for cancer or has cancer, particularly ovarian cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion and/or addition and/or substitution  
30 of one or more nucleotides from Ovr107, a chromosomal rearrangement of Ovr107, aberrant modification of Ovr107 (such as of the methylation pattern of the genomic DNA), the presence of a non-wild type splicing pattern of a mRNA transcript of Ovr107, allelic loss of Ovr107, and/or  
35 inappropriate post-translational modification of Ovr107

03747883 112100

protein. Methods to detect such lesions in Ovr107 of this invention are known to those of skill in the art.

## Assay Techniques

Assay techniques that can be used to determine levels of gene expression (including protein levels), such as Ovr107 of the present invention, in a sample derived from a human are well-known to those of skill in the art. Such assay methods include radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches, 2-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to Ovr107, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to Ovr107. The reporter antibody is attached to a detectable reagent such as a radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to Ovr107 is  
25 incubated on a solid support, e.g., a polystyrene dish, that  
binds the antibody. Any free protein binding sites on the  
dish are then covered by incubating with a non-specific  
protein such as bovine serum albumin. Next, the sample to be  
analyzed is incubated in the dish, during which time Ovr107  
30 binds to the specific antibody attached to the polystyrene  
dish. Unbound sample is washed out with buffer. A reporter  
antibody specifically directed to Ovr107 and linked to a  
detectable reagent such as horseradish peroxidase is placed  
in the dish resulting in binding of the reporter antibody to  
35 any monoclonal antibody bound to Ovr107. Unattached reporter

antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to Ovr107 antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of Ovr107 protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay can also be employed wherein antibodies specific to Ovr107 are attached to a solid support and labeled Ovr107 and a sample derived from the patient or human control are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of Ovr107 in the sample.

Using all or a portion of a nucleic acid sequence of Ovr107 of the present invention as a hybridization probe, nucleic acid methods can also be used to detect Ovr107 mRNA as a marker for cancer, including ovarian cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect



the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the Ovr107 gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the Ovr107 gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative

abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) obtained from the patient including tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

#### ***In Vivo Targeting of Ovr107/Cancer Therapy***

Identification of Ovr107 is also useful in the rational design of new therapeutics for imaging and treating cancers, and in particular ovarian cancer. For example, in one embodiment, antibodies which specifically bind to Ovr107 can be raised and used *in vivo* in patients suspected of suffering from cancer. Antibodies which specifically bind a Ovr107 can be injected into a patient suspected of having cancer for diagnostic and/or therapeutic purposes. The preparation and use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscentographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against Ovr107 can be used in a similar manner. Labeled antibodies which specifically bind Ovr107 can be injected into patients suspected of having cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with

the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as  
5 Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadolinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or tissue also  
10 allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with cancer, and in particular ovarian cancer, injection of an antibody which specifically binds Ovr107 can also have a therapeutic benefit. The  
15 antibody may exert its therapeutic effect alone. Alternatively, the antibody can be conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin,  
20 Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor  
25 while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against Ovr107.

30 Antibodies which can be used in these *in vivo* methods include polyclonal, monoclonal and omniclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro*

0071783-14100

evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

### ***Screening Assays***

The present invention also provides methods for  
5 identifying modulators which bind to Ovr107 protein or have  
a modulatory effect on the expression or activity of Ovr107  
protein. Modulators which decrease the expression or activity  
of Ovr107 protein are believed to be useful in treating  
cancer. Such screening assays are known to those of skill in  
10 the art and include, without limitation, cell-based assays and  
cell free assays.

Small molecules predicted via computer imaging to  
specifically bind to regions of Ovr107 can also be designed,  
synthesized and tested for use in the imaging and treatment  
15 of cancer. Further, libraries of molecules can be screened  
for potential anticancer agents by assessing the ability of  
the molecule to bind to Ovr107. Molecules identified in the  
library as being capable of binding to Ovr107 are key  
candidates for further evaluation for use in the treatment of  
20 cancer. In a preferred embodiment, these molecules will  
downregulate expression and/or activity of Ovr107 in cells.

### ***Adoptive Immunotherapy and Vaccines***

Adoptive immunotherapy of cancer refers to a therapeutic  
approach in which immune cells with an antitumor reactivity  
25 are administered to a tumor-bearing host, with the aim that  
the cells mediate either directly or indirectly, the  
regression of an established tumor. Transfusion of  
lymphocytes, particularly T lymphocytes, falls into this  
category and investigators at the National Cancer Institute  
30 (NCI) have used autologous reinfusion of peripheral blood  
lymphocytes or tumor-infiltrating lymphocytes (TIL), T cell  
cultures from biopsies of subcutaneous lymph nodes, to treat  
several human cancers (Rosenberg, S. A., U.S. Patent No.  
4,690,914, issued Sep. 1, 1987; Rosenberg, S. A., et al.,  
35 1988, N. England J. Med. 319:1676-1680).

The present invention relates to compositions and methods of adoptive immunotherapy for the prevention and/or treatment of cancer in humans using macrophages sensitized to the antigenic Ovr107 molecules, with or without non-covalent  
5 complexes of heat shock protein (hsp). Antigenicity or immunogenicity of Ovr107 is readily confirmed by the ability of the Ovr107 protein or a fragment thereof to raise antibodies or educate naive effector cells, which in turn lyse target cells expressing the antigen (or epitope).

10 Cancer cells are, by definition, abnormal and contain proteins which should be recognized by the immune system as foreign since they are not present in normal tissues. However, the immune system often seems to ignore this abnormality and fails to attack tumors. The foreign Ovr107  
15 proteins that are produced by the cancer cells can be used to reveal their presence. Ovr107 is broken into short fragments, called tumor antigens, which are displayed on the surface of the cell. These tumor antigens are held or presented on the cell surface by molecules called MHC, of which there are two  
20 types: class I and II. Tumor antigens in association with MHC class I molecules are recognized by cytotoxic T cells while antigen-MHC class II complexes are recognized by a second subset of T cells called helper cells. These cells secrete cytokines which slow or stop tumor growth and help another  
25 type of white blood cell, B cells, to make antibodies against the tumor cells.

In adoptive immunotherapy, T cells or other antigen presenting cells (APCs) are stimulated outside the body (ex vivo), using the tumor specific Ovr107 antigen. The stimulated cells are then reinfused into the patient where they attack the cancerous cells. Research has shown that using both cytotoxic and helper T cells is far more effective than using either subset alone. Additionally, the Ovr107 antigen may be complexed with heat shock proteins to stimulate the APCs as described in U.S. Patent No. 5,985,270.

The APCs can be selected from among those antigen presenting cells known in the art including, but not limited to, macrophages, dendritic cells, B lymphocytes, and a combination thereof, and are preferably macrophages. In a preferred use, wherein cells are autologous to the individual, autologous immune cells such as lymphocytes, macrophages or other APCs are used to circumvent the issue of whom to select as the donor of the immune cells for adoptive transfer. Another problem circumvented by use of autologous immune cells is graft versus host disease which can be fatal if unsuccessfully treated.

In adoptive immunotherapy with gene therapy, DNA of Ovr107 can be introduced into effector cells similarly as in conventional gene therapy. This can enhance the cytotoxicity of the effector cells to tumor cells as they have been manipulated to produce the antigenic protein resulting in improvement of the adoptive immunotherapy.

Ovr107 antigens of this invention are also useful as components of cancer vaccines. The vaccine comprises an immunogenically stimulatory amount of an Ovr107 antigen. Immunogenically stimulatory amount refers to that amount of antigen that is able to invoke the desired immune response in the recipient for the amelioration, or treatment of cancer. Effective amounts may be determined empirically by standard procedures well known to those skilled in the art.

The Ovr107 antigen may be provided in any one of a number of vaccine formulations which are designed to induce the desired type of immune response, e.g., antibody and/or cell mediated. Such formulations are known in the art and include, but are not limited to, formulations such as those described in U.S. Patent 5,585,103. Vaccine formulations of the present invention used to stimulate immune responses can also include pharmaceutically acceptable adjuvants.

**EXAMPLE**

The present invention is further described by the following example. The example is provided solely to illustrate the invention by reference to specific embodiments.

5 This exemplification, while illustrating certain specific aspects of the invention, does not portray the limitations or circumscribe the scope of the disclosed invention.

Experiments described herein were carried out using standard techniques, which are well known and routine to those  
10 of skill in the art, except where otherwise described in detail. Routine molecular biology techniques were carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.  
15 (1989).

**Relative Quantitation of Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase. The method uses an  
20 internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection  
25 System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  
30 or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained

0074883 112100  
0074883 112100

using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene were evaluated for every sample in normal and cancer tissue.

5 Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target  
10 gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Primers used for expression analysis include:

15 Reverse: 5'-CCCAATAGCGGAAGTCGATCT-3' (SEQ ID NO:2)

Forward: 5'-CACTCCCAGCCAGTCCAGAT-3' (SEQ ID NO:3)

Ovr107 Probe: 5'-AATCTGCTCCGGCCCTGGTCTT-3' (SEQ ID NO:4)

The absolute numbers depicted in Table 1 are relative levels of expression of Ovr107 (also referred to as Clone ID  
20 817834; Gene ID 403869) in 12 normal different tissues. All the values are compared to normal pancreas (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

25 **Table 1: Relative Levels of Ovr107 Expression in Pooled Samples**

TISSUE	NORMAL
Ascending Colon	14.47
Endometrium	8.60
30 Kidney	2.64
Liver	0.08
Ovary	1.46
Pancreas	1.00
Prostate	17.22
35 Small Intestine	4.96
Spleen	2.86
Stomach	38.59
Testis	4.18
Uterus	13.45



The relative levels of expression in Table 1 show that Ovr107 is expressed in all the normal tissues analyzed. Stomach shows the highest relative expression level with 38.59, and liver the lowest expression value with 0.08.

5 The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.

10 The absolute numbers depicted in Table 2 are relative levels of expression of Ovr107 in 47 pairs of matching samples. All the values are compared to normal pancreas (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.  
15 In addition, 12 unmatched cancer samples (from ovary) and 14 unmatched normal samples (from ovary) were also tested.

**Table 2: Relative Levels of Ovr107 Expression in Individual Samples**

20	<b>Sample ID</b>	<b>Tissue</b>	<b>Cancer</b>	<b>Matching Normal Adjacent</b>	<b>Normal</b>
	Ovr103X	Ovary 1	93.4		1.30
	Ovr1028	Ovary 2	182.90		
	Ovr10050	Ovary 3	113.31		
25	Ovr1040	Ovary 4	132.50		
	Ovr130X	Ovary 5	14.98		
	Ovr638A	Ovary 6	102.89		
	Ovr7730	Ovary 7	57.68		
	OvrA1B	Ovary 8	50.91		
30	OvrA1C	Ovary 9	68.59		
	Ovr1157	Ovary 10	146.02		

00777 "E887T260

5	Ovr1118	Ovary 11	3.85		
	OvrC360	Ovary 12	2.91		
	Ovr63A	Ovary 13	0.25		
	Ovr35GA	Ovary 14			2.00
	Ovr18GA	Ovary 15			1.94
10	Ovr206I	Ovary 16			2.11
	Ovr20GA	Ovary 17			1.91
	Ovr25GA	Ovary 18			3.78
	Ovr32RA	Ovary 19			1.72
	Ovr506B	Ovary 20			0.57
15	OvrC007	Ovary 21			0.28
	OvrC004	Ovary 22			0.57
	Ovr40G	Ovary 23			0.60
	Ovr9RA	Ovary 24			1.82
	OvrC087	Ovary 25			0.46
20	OvrC109	Ovary 26			2.35
	OvrC179	Ovary 27			2.12
	Pan71XL	Pancreas	7.14	1.19	
	Pro34B	Prostate	19.36	11.84	
	SmIH89	Small Intestine 1	13.88	2.20	
25	SmI21XA	Small Intestine 2	1.10	0.50	
	Tst39X	Testis	6.94	2.02	
	Utr141XO	Uterus 1	18.57	5.45	
	Utr23XU	Uterus 2	22.39	5.50	
	Utr135XO	Uterus 3	19.00	20.70	
30	Utr85XU	Uterus 4	26.00	21.90	
	Bld66X	Bladder 1	10.74	1.47	
	End28XA	Endometrium 1	100.78	17.88	
	End5XA	Endometrium 2	14.52	30.80	
	End8XA	Endometrium 3	2.17	20.04	

PATENT "E2B/T/60"

5	End65RA	Endometrium 4	32.67	7.89	
	End8963	Endometrium 5	21.63	4.59	
	End10479	Endometrium 6	130.20	16.10	
	End12XA	Endometrium 7	41.60	13.30	
	End3AX	Endometrium 8	3.00	7.50	
10	End68X	Endometrium 9	25.00	35.00	
	End8911	Endometrium 10	28.00	24.00	
	Kid80XD	Kidney 1	1.48	2.76	
	Kid6XD	Kidney 2	44.63	2.66	
	Kid5XD	Kidney 3	18.10	1.30	
15	Kid98XD	Kidney 4	5.40	3.40	
	Liv15XA	Liver 1	0.03	0.08	
	Liv94XA	Liver 2	5.19	0.30	
	LngAC82	Lung 1	2.23	2.08	
	LngAC88	Lung 2	17.15	9.45	
20	Lng60XL	Lung 3	35.75	4.99	
	LngAC69	Lung 4	108.40	11.40	
	LngSQ32	Lung 5	86.50	23.90	
	MamA06X	Mammary Gland 1	9.45	0.06	
	MamB011X	Mammary Gland 2	5.31	1.27	
25	Mam47XP	Mammary Gland 3	0.80	0.20	
	Mam59X	Mammary Gland 4	23.40	1.40	
	Mam12X	Mammary Gland 5	5.12	5.43	
	ClnC9XR	Colon 1	7.52	2.52	
	ClnCM67	Colon 2	1.78	0.30	
30	ClnAS67	Colon 3	3.71	12.30	
	ClnRC67	Colon 4	9.40	7.80	
	ClnTX67	Colon 5	42.40	3.30	
	StoAC44	Stomach 1	12.00	38.00	
	StoAC93	Stomach 2	24.00	62.00	

OFFICE OF THE CLERK

StoAC99	Stomach 3	62.00	34.00	
StoMT54	Stomach 4	49.00	19.00	
StoTA73	Stomach 5	99.00	51.00	

Table 1 and Table 2 represent a combined total of 132 samples in 15 different tissue types.

As shown in Table 2, all 120 samples from 14 different tissues analyzed, showed expression of Ovr107 (expression values > 0.00)

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared, with the exception of the unmatched ovarian samples. This comparison provides an indication of specificity for cancer (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of Ovr107 in 35 of 47 (74%) matching samples analyzed (ovary 1, pancreas, prostate, small intestine 1 and 2, testis, uterus 1, 2 and 4, bladder, endometrium 1, 4, 5, 6, 7, and 10, kidney 2, 3 and 4, liver 2, lung 2, 3, 4, and 5, mammary gland 1, 2, 3, and 4, colon 1, 2, 4, and 5, and stomach 3, 4, and 5).

For the unmatched ovarian samples, 11 of 13 (85%), cancer samples show expression values of Ovr107 higher than the median (1.82) for the normal unmatched ovarian samples, and 10 of 13 (77%) show expression higher than the highest level seen in normal ovary.

Altogether, the broad tissue distribution, plus the mRNA overexpression in a majority of cancer samples compared to normal are indicative of Ovr107 being a marker not only for ovarian cancer, but for cancer in general.

**What is claimed is:**

1. A diagnostic marker for cancer comprising Ovr107.
2. The diagnostic marker of claim 1 where Ovr107 comprises SEQ ID NO:1.
- 5 3. A method for diagnosing the presence of cancer in a patient comprising:
  - (a) determining levels of Ovr107 in cells, tissues or bodily fluids in a patient; and
  - (b) comparing the determined levels of Ovr107 with levels  
10 of Ovr107 in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of Ovr107 in said patient versus normal human control is associated with the presence of cancer.
4. A method of diagnosing metastases of cancer in a  
15 patient comprising:
  - (a) identifying a patient having cancer that is not known to have metastasized;
  - (b) determining Ovr107 levels in a sample of cells, tissues, or bodily fluid from said patient; and
  - 20 (c) comparing the determined Ovr107 levels with levels of Ovr107 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined Ovr107 levels in the patient versus the normal human control is associated with a cancer which has metastasized.
- 25 5. A method of staging cancer in a patient having cancer comprising:
  - (a) identifying a patient having cancer;
  - (b) determining Ovr107 levels in a sample of cells, tissue, or bodily fluid from said patient; and
  - 30 (c) comparing determined Ovr107 levels with levels of Ovr107 in cells, tissues, or bodily fluid of a normal human

09717883-112100

control, wherein an increase in determined Ovr107 levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined Ovr107 levels is associated with a cancer which is  
5 regressing or in remission.

6. A method of monitoring cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having cancer that is not known to have metastasized;

10 (b) periodically determining levels of Ovr107 in samples of cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Ovr107 levels with levels of Ovr107 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the  
15 periodically determined Ovr107 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

7. A method of monitoring a change in stage of cancer in a patient comprising:

20 (a) identifying a patient having cancer;

(b) periodically determining levels of Ovr107 in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Ovr107 levels with levels of Ovr107 in cells, tissues, or bodily fluid of  
25 a normal human control, wherein an increase in any one of the periodically determined Ovr107 levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

30 8. A method of identifying potential therapeutic agents for use in imaging and treating cancer comprising screening molecules for an ability to bind to Ovr107 wherein the ability

09783112100

of a molecule to bind to Ovr107 is indicative of the molecule being useful in imaging and treating cancer.

9. An antibody which specifically binds Ovr107.

5 10. A method of imaging cancer in a patient comprising administering to the patient the antibody of claim 9.

11. The method of claim 10 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10 12. A method of treating cancer in a patient comprising administering to the patient the antibody of claim 9.

13. The method of claim 12 wherein the antibody is conjugated to a cytotoxic agent.

15 14. A method of treating cancer in a patient comprising administering to the patient a molecule which downregulates expression or activity of Ovr107.

20 15. A method of inducing an immune response against a target cell expressing Ovr107 comprising delivering to a human patient an immunogenically stimulatory amount of an Ovr107 protein so that an immune response is mounted against the target cell.

16. A vaccine for treating cancer comprising Ovr107.

00727" 000760

**ABSTRACT**

The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancer.

00123456789



Docket No.  
DEX-0115

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING CANCER**

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as United States Application No. or PCT International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day/Month/Year Filed)

☐

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day/Month/Year Filed)

☐

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day/Month/Year Filed)

☐

<u>60/166,818</u>	<u>November 22, 1999</u>
(Application Serial No.)	(Filing Date)

(Application Serial No.) \_\_\_\_\_ (Filing Date) \_\_\_\_\_

(Application Serial No.)	(Filing Date)
--------------------------	---------------

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	--

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	--

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



**26259**

PATENT TRADEMARK OFFICE

Send Correspondence to: **Kathleen A. Tyrrell**  
**Licata & Tyrrell P.C.**  
**66 E. Main Street**  
**Marlton, NJ 08053**

Direct Telephone Calls to: *(name and telephone number)*  
**Kathleen A. Tyrrell, Tel: 856-810-1515**

Full name of sole or first inventor <b>Susana Salceda</b>	
Sole or first inventor's signature	Date
Residence <b>San Jose, CA</b>	
Citizenship <b>Argentina</b>	
Post Office Address <b>4118 Crescendo Avenue</b>	
<b>San Jose, CA 95136</b>	

Full name of second inventor, if any <b>Robert Cafferkey</b>	
Second inventor's signature	Date
Residence <b>San Jose, CA</b>	
Citizenship <b>Ireland</b>	
Post Office Address <b>350 Elan Village Lane, Apt. 218</b>	
<b>San Jose, CA 95134</b>	

Full name of third inventor, if any <b>Xing Jian Lou</b>	
Third inventor's signature	Date
Residence <b>Mountain View, CA</b>	
Citizenship <b>US</b>	
Post Office Address <b>465 Chiquita Avenue, #3</b>	
<b>Mountain View, CA 94014</b>	

Full name of fourth inventor, if any <b>Herve Recipon</b>	
Fourth inventor's signature	Date
Residence <b>San Francisco, CA</b>	
Citizenship <b>France</b>	
Post Office Address <b>85 Fortuna Avenue</b>	
<b>San Francisco, CA 94115</b>	

Full name of fifth inventor, if any <b>Yongming Sun</b>	
Fifth inventor's signature	Date
Residence <b>San Jose, CA</b>	
Citizenship <b>China</b>	
Post Office Address <b>869 S. Winchester Boulevard, Apt. 260</b>	
<b>San Jose, CA 95128</b>	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

# SEQUENCE LISTING

<110> Salceda, Susana  
Cafferkey, Robert  
Lou, Xing Jian  
Recipon, Herve  
Sun, Yongming

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,  
IMAGING AND TREATING CANCER

<130> DEX-0115

<140>

<141>

<150> 60/166,818

<151> 1999-11-22

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 1635

<212> DNA

<213> Homo sapiens

<400> 1

```
tcgcggccgc aggagccggc gccgggcggc tggggagggc ttgctgacgc tgcggggccaa 60
gccgccctcg gaggccgagt acaccgacgt gctgcagaag atcaagtacg ccttcagcct 120
gctggcccgg ctgcgcggca acatcgccga cccctcctct ccggagctgt tgcacttcct 180
tttcgggcct ctgcagatga ttgtgaacac gtcggggggg ccggagttcg cgagcagtg 240
gcgccggccg catctgacat cggatgccgt ggcgctgctg cgggacaacg tccactccacg 300
tgaaaacgag ctctggacct cgctggggga ctcgtggacc cgccccgggc tggagctgtc 360
cccggaggag ggacccccat acagaccgga gttcttcagc ggctgggagc cgccgggtcac 420
tgaccgcgag agccgcgcct gggaggaccc agttgagaaa cagctacagc acgagcggag 480
gcgccggcag caaagcgccc ccgaggtcgc tgtcaatggc caccgaggac ttgggagcca 540
gaatctgagc ctgagctgga gtcagagaca gcaggaaaat gggctcctgtg taattatgac 600
ttccaggccc gcaacagcag tgagctgtcg gtcaagcagc gggacgtact ggaggtcctg 660
gatgacagtc gtaagtgggtg gaaggttcgg gaccacgcgg ggcaggaggg atatgtgccc 720
tacaacatcc tgacacccta ccccggaacc cggtgcacc acagccaaag ccctgcccgc 780
agcctgaaca gactcctcc tccaccacca gcccagccc cgccccacc tccagctctg 840
gctcggcccc gctgggacag gccccgctgg gacagctgcg atanctcaac ggcttgagac 900
ccagcgagaa ggagaaattc tcccagatgc tcatcgtaa cgaggaactg caggcgcgcc 960
tggcccaggg ccgctcggga ccgagccgcg cagtcccagg gccccgcgcc ccggaaccgc 1020
agctcagccc gggctcggac gcctccgang tccgcgcctg gctgcaggnc aagggttta 1080
gctccgggac cgtggacgcg ctgggtgtgc tgaccggggc gcacttttct cgctgcagaa 1140
```

```

ggaggagctg cgggcggtga gccccgagga gggggcacgt gtgtacagcc aggtcaccgt 1200
gcagcgcttc gctgctggag gacaaagaga aagtgtcaga gctggaggca gtgatggaga 1260
agcaaaagaa gaagggtgaa ggcgaggtgg aaatggaggt catttgacct gccaggcgcc 1320
cttcgcaaag agtgacgagg ccccgaggga gaacggactc ctcagactct cccaatagc 1380
ggaagtcat cttctgaagg atggccaatc tgctccggcc ctggtcttcc cccatcccgg 1440
tggacagact taacgatcct tgctgcagtc cctccggaga ggatctggac tggctgggag 1500
tggggagggc gtggagacag tctacggaaa gcgctagcag acccccgaga gggtgagtg 1560
gagccctgag cattgtaata tgcgggccag cctataaaca gcctccgtgc ttagcagatg 1620
gtgtgccant tnaaa 1635

```

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 2

cccaatagcg gaagtcgatc t 21

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 3

cactcccagc cagtccagat 20

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 4

aatctgctcc ggccctggtc tt 22